News stories about Mednax (NYSE:MD) have been trending somewhat positive this week, Alpha One reports. The research group, a service of Accern, rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Mednax earned a news impact score of 0.19 on Alpha One’s scale. Alpha One also gave news headlines about the company an impact score of 44 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected AlphaOne Sentiment’s rankings:
- ETFs with exposure to MEDNAX, Inc. : June 19, 2017 (finance.yahoo.com)
- MEDNAX, Inc. :MD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 (finance.yahoo.com)
- Snap Has Shed an Astounding $13 Billion in Value and Now the Stock Is Trading Near Its IPO Price (finance.yahoo.com)
- MEDNAX : Ziegler Named Finalist for ACG New York’s “Champion’s Award” for Healthcare/Pharma Deal of the Year (4-traders.com)
- MEDNAX (MD) Presents At The William Blair 2017 Growth Stock Conference – Slideshow (seekingalpha.com)
A number of analysts have weighed in on the stock. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a research report on Wednesday, March 15th. Robert W. Baird downgraded shares of Mednax from an “outperform” rating to a “neutral” rating and set a $72.00 target price for the company. in a research report on Tuesday, March 21st. J P Morgan Chase & Co reissued a “neutral” rating and set a $69.00 target price on shares of Mednax in a research report on Friday, March 10th. Jefferies Group LLC reissued a “hold” rating on shares of Mednax in a research report on Monday, April 10th. Finally, Bank of America Corporation downgraded shares of Mednax from a “buy” rating to an “underperform” rating in a research report on Thursday, May 4th. Two research analysts have rated the stock with a sell rating and ten have assigned a hold rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $66.25.
Mednax (MD) traded up 0.49% during mid-day trading on Monday, reaching $56.87. 919,166 shares of the company traded hands. The stock has a market capitalization of $5.25 billion, a price-to-earnings ratio of 16.98 and a beta of 0.52. The company’s 50-day moving average is $55.93 and its 200-day moving average is $65.04. Mednax has a 12-month low of $53.80 and a 12-month high of $76.96.
Mednax (NYSE:MD) last issued its quarterly earnings results on Thursday, May 4th. The company reported $0.75 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.01. The company had revenue of $835.60 million for the quarter, compared to analysts’ expectations of $837.01 million. Mednax had a return on equity of 12.81% and a net margin of 9.54%. The firm’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.87 earnings per share. Equities analysts predict that Mednax will post $3.61 earnings per share for the current fiscal year.
In other news, insider Joseph M. Calabro sold 23,327 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $55.00, for a total value of $1,282,985.00. Following the sale, the insider now directly owns 296,379 shares of the company’s stock, valued at $16,300,845. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Vivian Lopez-Blanco sold 7,778 shares of the stock in a transaction on Friday, May 5th. The stock was sold at an average price of $55.82, for a total value of $434,167.96. Following the completion of the sale, the chief financial officer now directly owns 51,319 shares in the company, valued at $2,864,626.58. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,074 shares of company stock worth $1,830,508. 2.40% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Mednax (MD) Share Price” was originally published by sleekmoney and is the property of of sleekmoney. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://sleekmoney.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mednax-md-share-price/1923083.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-mednax-md-share-price/1923083.html
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.